Qilu harvest! Take 13 heavy-weight varieties, 38 over-rated varieties to lead, 8 large collection varieties ready to develop.

Exciting content Recently, Qilu Pharmaceutical'sacid siding that non-film was approved and treated as a review.
this year, Qilu pharmaceutical drugs have been approved, the news of evaluation, 2020 has been approved 13 varieties listed;
addition, 35 generic (newly registered classifications) were listed for review, mostly anti-tumor and systemic anti-infectant drugs.
the third batch of collection will be opened on August 20, Qilu Pharmaceuticals as a "barefoot" enterprises, 8 shortlisted varieties will be a big show.
a good harvest of generic drugs! Take this year's 13th new product August 7, NMPA official website shows that Qilu Pharmaceuticals according to the imitation of 4 categories of reportedacid sidna non-tablets were approved for market and as if through consistency evaluation.
is a type 5 type of phosphate degesterase (PDE-5) selective inhibitor, is currently one of the world's main products against ED (erectile dysfunction).
is the third batch of collected varieties, in 2019 in China's urban retail pharmacy terminal sales of more than 2.3 billion yuan, Qilu Pharmaceuticals successfully won the bid before the opening of the variety tickets.
is worth mentioning thatis the 13th new product approved by Qilu Pharmaceuticals this year.
this year, Qilu pharmaceutical drugs have been approved, the news of evaluation continues.
meters intranet data show that the number of varieties approved for listing in Qilu Pharmaceuticals so far in 2020 has been the same as the number of approved varieties in 2019 (13), the number of approved varieties for the whole year will certainly exceed 2019.
of the 13 newly approved generic drugs approved for sale by Qilu Pharmaceuticals since 2020, the remaining 12 varieties were approved according to the new registration classification, with the same as the adoption of a consistency evaluation.
5 varieties, such as Bivalding, Pribarin capsules, lefluomide tablets, Osali platinum injections, and aspirin capsules, were the first to be evaluated.
addition, the aspirin capsule is the first replica taken by Qilu Pharmaceuticals this year, the world's first approved NK-1-like antagonist anti-spitting drug.
35 new products on the road, deep into two hundred billion market Qilu Pharmaceutical in the review of the new registration classification generic drug Mi net data show that Qilu Pharmaceutical in the review of the new registered classification of generic drugs produced by 35 varieties (70 acceptance numbers), approved for production will be treated as a consistent evaluation.
From the contractor time point of view, this year Qilu pharmaceutical application for the listing of only 6 varieties of generic drugs, and high-barrier generic drugs, respectively, injection with fusapitan double phosphonate, injection with acetic acid capofen net, cisplatin injection, hydrochloric acid moxisa star drop eye drops, methionate lunphate capsules, taurine bromide brominated eye drops.
11 of the 35 varieties in the domestic market have not been approved for the market, Qilu will compete with a number of pharmaceutical companies for the first generic.
Among them, four varieties, such as perpenibani tablets, pyrethroid capsules, methicillin resagegylan tablets, metformin viglitin tablets, were first reported by Qilu Pharmaceuticals, and sodium cephalosporine Avebatan for injection was exclusively reported by Qilu Pharmaceuticals.
for these five varieties, Qilu Pharmaceuticals will have a good chance of winning the first imitation.
from the field of drug treatment, Qilu Pharmaceuticals in the review of 35 varieties of anti-tumor drugs and systemic anti-infective drugs mainly.
10 varieties of anti-tumor and immunomodulants, with 8 varieties of anti-infective drugs in the whole body ranking second and 6 varieties of neurological drugs. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) end-use anti-infective drugs, anti-tumor and immunomodulant sales of more than 100 billion yuan.
38 over-rated varieties lead the way, 8 large collection of varieties ready to be issued so far, Qilu Pharmaceuticals has 38 varieties (66 product rules) through or as if through the consistency evaluation, of which 22 varieties for the first domestic evaluation.
Hydrochloric acid ondanscong tablets, ammonia-based pills, lipe ketone mouth collapse tablets, huafalin sodium tablets, injection-based bivaladtin, Pribarin capsules, isemetan tablets, O'Shali platinum injections, cephalosporine particles, mononitric isopolycerides slow release tablets, aripitan capsules and other 11 varieties for Qilu Pharmaceutical exclusive review.
of the 38 over-evaluated varieties evaluated by Qilu Pharmaceuticals through/assimilar by consistency, 16 were evaluated by Qilu Pharmaceuticals in 2020.
It is worth mentioning that in the evaluation of generic drug consistency, Qilu Pharmaceutical's variety evaluation number has always been in a leading position, with 38 varieties (66 product rules) leading the consistent evaluation list, Yangzijiang Pharmaceutical Group with 34 varieties (40 product rules) ranked second, China Biopharmaceuticals with 33 varieties (39 product rules) ranked third.
a wealth of over-evaluation varieties to help Qilu Pharmaceuticals in the national volume procurement.
"4 plus 7" enlargement, Qilu Pharmaceutical's Atovastatin calcium tablets, o nitrogen flat tablets, lipe ketone tablets, gefetini tablets, fumaric acid nofovedimate tablets And so on 5 varieties winning the bid; in the second batch, Qilu Pharmaceutical's Adelfowe ester tablets, hydrochloric acid quercetazine slow release tablets, amber acid Solina new tablets, Tiggio capsules and other 4 varieties winning the bid.
the third batch of 56 generic varieties, Qilu Pharmaceuticals has 8 over-rated varieties in the column.
from the evaluation situation, Menglust sodium chewing tablets, Viglitin tablets over-evaluation enterprises as many as 7, apixaban tablets have 6 enterprises over-reviewed, O nitrogen flat mouth collapse tablets,acid to Fati cloth film has 5 enterprises have been evaluated, the competition is more intense, Capatham film, relying on the kaoxi film,acid West Didi non-film evaluation enterprises are 2, 2, 3, the competition pattern is relatively friendly.
of the 8 varieties in the competition pattern of the third batch of collecting varieties of Qilu Pharmaceuticals, only capertabin tablets and Viglitin tablets were evaluated by means of consistent evaluation of supplementary applications.
Qilu Pharmaceutical's Capetabin tablet has been on the market for many years, with terminal sales of more than 200 million yuan in China's public medical institutions in 2019, Viglitin tablet was approved for listing in March 2019, reviewed in October 2019, and the remaining six over-evaluated varieties were approved for listing in 2019 and 2020, and the market is yet to be opened.
as a "barefoot" enterprise, qilu pharmaceutical will not miss the collection of this market development, rapid release of large opportunities!